News
Synchron Returns to Melbourne for First Trial of Next-Generation Stentrode
The FOCUS-AU trial will test Synchron's advanced brain-computer interface in ten MND patients across three Australian hospitals, with surgery beginning in April.
Market Moves
Merge Labs' $252M Bet on Ultrasound BCI Faces Scientific Scrutiny
Sam Altman's brain-computer interface startup raised the second-largest BCI round in history. The scientific community is asking whether the physics adds up.
Market Moves
Octane's Neuro Tech Forum Draws J&J, Medtronic, and Blackrock Neurotech to Newport Beach
The second annual forum brought together device makers, investors, and six early-stage startups for two days of panels on BCI, neuromodulation, and digital health.
Policy & Regulation
UK Funds £1 Million Philosophy of Neurotechnology Research Lab
Four philosophers at Glasgow and Oxford will lead a new interdisciplinary lab examining the ethical and epistemological implications of brain-computer interfaces.
Industry News
China's Beinao-1 Reaches Five Patients With Semi-Invasive Brain Chip
Five patients now carry the coin-sized wireless implant that sits on the brain's protective membrane rather than penetrating tissue, with one ALS patient decoding nearly 100 Chinese words.
Industry News
Nia Therapeutics Wins FDA Breakthrough Designation for AI-Guided Memory Implant
The Pennsylvania company's 60-channel Smart Neurostimulation System is the first device to receive Breakthrough Device Designation for TBI-related memory loss.
Market Moves
Cambridge Innovation Institute Acquires Neurotech Reports After 25 Years of Independent Publishing
CII absorbs the neurotechnology sector's longest-running trade publication into its venture and innovation division, with founder James Cavuoto and team staying on.
Market Moves
Cleveland Startup Sells $350 Brain Stimulation Headset Without FDA Clearance While Clinical Trials Continue
U: The Mind Company began taking orders for a consumer neuromodulation device on March 18, marketing bold clinical claims that have not appeared in peer-reviewed literature. An FDA submission is planned for 2027.
Industry News
Flow Neuroscience Brings First FDA-Approved At-Home Brain Stimulation for Depression to US Market
The Swedish company's FL-100 headset, cleared via the FDA's most stringent PMA pathway, launches in the US in Q2 2026 after a 174-person Nature Medicine trial. A second device, Neurolief's ProlivRx, was approved weeks later.
Stay Ahead of the Curve
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.